-

Viz.ai Launches Viz™ Trauma Suite to Support Change in Trauma Center Standards

Tailored for trauma care providers to help expedite patient care and improve outcomes

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced at TraumaCon 2023 the introduction of Viz Trauma Suite, a software solution designed to support trauma care providers as they prepare to meet new requirements in the American College of Surgeons (ACS) trauma center standards. Viz.ai’s high-fidelity mobile viewer and communication platform will help to reduce team response times for trauma patients, enabling faster care and addressing resource constraints.

“We are excited to introduce Viz.ai’s capabilities to trauma care providers, especially with the changes to the requirements regarding response times, including interventional radiology response to hemorrhage control,” said Gad Sakin, chief product officer at Viz.ai. “With more than 35,000 healthcare providers already on the Viz.ai platform, trauma professionals can reach on-call radiologists and specialists immediately and get patients the care that they need.”

ACS is expected to begin verification visits in September 2023 based on the updated trauma center standards, which include new response times and resource availability. The Viz Trauma Suite provides a mobile and web high-fidelity image viewer that supports a wide range of modalities, including CT, CTA, MRI, X-Ray, EKG, echocardiogram and ultrasound, so that trauma care providers can easily access critical patient information in real-time. Viz.ai’s HIPAA-compliant communication tools enable seamless connection with the entire care team, including radiologists and specialists across the healthcare system, to coordinate and expedite patient care.

For more information, join the abstract presentation at TraumaCon on Friday at 7am Mountain time or visit www.viz.ai/trauma.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Contacts

Viz.ai, Inc.


Release Versions

Contacts

Social Media Profiles
More News From Viz.ai, Inc.

Viz.ai Wins 2025 Edison Award™ for Machine Learning Innovation for the Third Consecutive Year

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has been named an Award Winner in the 2025 Edison Awards, for the third year in a row. Viz HCM, the company’s AI software solution designed to detect and triage patients with signs of hypertrophic cardiomyopathy (HCM), was recognized in the Health Medical & Biotech category and Cardiovascular Health Diagnostics and Monitoring subcategory. The Edison A...

Four New Studies Demonstrate that Viz.ai Finds New Patients with Hypertrophic Cardiomyopathy Earlier When Embedded into the Clinical Workflow

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data demonstrating how the Viz HCM module enables faster, accurate detection of signs of hypertrophic cardiomyopathy (HCM) to help ensure that more patients receive the care they need. Four studies, which will be presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo 2025, show the real-world impact of Viz.ai in...

New Study Demonstrates Significant Impact of AI-Powered Communication in Stroke Patients with Cardiac Shunts

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data from the study PFO-ACCESS: Augmenting Communications for Medical Care or Closure in the Evaluation of Stroke Patients With Cardiac Shunts demonstrating the impact of the Viz Connect® module in improving cryptogenic stroke patient management. The study results were presented by Yasaman Pirahanchi, MD, Vascular Neurology Fellow at UC San Diego, du...
Back to Newsroom